Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
Yoshiyuki NagumoMizuki OnozawaTakahiro KojimaNaoki TeradaMasaki ShiotaKoji MitsuzukaHiroaki YasumotoHiroaki MatsumotoHideki EnokidaTakayuki SugiyamaKentaro KuroiwaToshihiro SaitoAkira YokomizoNaoki KoheiKen-Ichi TabataAtsushi TakahashiMikio SugimotoHiroshi KitamuraToshiyuki KamotoHiroyuki Nishiyamanull nullPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
In the high-burden group, combined androgen blockade with a first-generation anti-androgen resulted in superior progression-free survival compared with castration monotherapy. For well-selected metastatic hormone-sensitive prostate cancer patients, the use of combined androgen blockade might still have some suitable scenarios.